However, we did not observe similar findings because in our study, 6 of 34 (17.6%) patients with MSH2/MSH6 loss and 5 of 81 (6.2%) MLH1/PMS2 loss patients developed metachronous CRC. This evidence concerns the gene MSH2 and colorectal carcinoma.